Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBT Margin (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of EBT Margin readings, the most recent being 29.33% for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin fell 9424.0% year-over-year to 29.33%, compared with a TTM value of 2.4% through Dec 2025, up 531.0%, and an annual FY2025 reading of 2.4%, up 531.0% over the prior year.
  • EBT Margin hit 29.33% in Q4 2025 for Apellis Pharmaceuticals, down from 47.17% in the prior quarter.
  • The five-year high for EBT Margin was 470.64% in Q4 2021, with the low at 35183.15% in Q2 2021.
  • Median EBT Margin over the past 5 years was 55.09% (2025), compared with a mean of 2214.85%.
  • The largest YoY upside for EBT Margin was 3423050bps in 2022 against a maximum downside of -84414bps in 2022.
  • Year by year, EBT Margin stood at 470.64% in 2021, then crashed by -179bps to 373.5% in 2022, then skyrocketed by 93bps to 26.41% in 2023, then skyrocketed by 346bps to 64.91% in 2024, then crashed by -145bps to 29.33% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 29.33%, 47.17%, and 23.35% for Q4 2025, Q3 2025, and Q2 2025 respectively.